ED use made 17 759 visits over the study period, while the 1928 patients with frequent ED use made 12 289 visits. Approximately half (49.8%) of all ED visits occurred on weekdays, while BMC primary care practices were open. Most ED visits were for low-severity conditions. Comment. Emergency department use by primary care patients at an urban safety-net hospital was high, though most visits were of low severity. One possible reason for this is lack of access to primary care, 4 with few available appointments to see a PCP. While data on time to third next available appointment, a standard measure of primary care access, 5 are not available for the primary care practices during the study period, other practice metrics suggest that access may have been a problem. For example, missed primary care appointment rates were high, averaging 24.5%. High missed appointment rates are often correlated with long wait times to schedule appointments. 6 In addition, monthly telephone call statistics show that only between 72.4% and 88.1% of patient telephone calls were answered by the primary care call center over the study period. It is possible that patients called the practices with an urgent problem, did not have their telephone call answered promptly, and decided to seek care in the ED instead. Indeed, 13% of telephone calls were abandoned by patients over the study period (patients called and subsequently hung up while they were kept on hold). The fact that nearly half of all ED visits took place during the hours of primary care clinic operation further suggests that appointment availability may have been an issue. In addition, a sizable minority, roughly one-fifth, of primary care is provided by residents, 7 who have limited availability when they are not in clinic. It is also possible that Massachusetts health reform has affected access to primary care. As newly insured patients have entered primary care in large numbers, it is possible that access to primary care has worsened for other patients.
Proton Beam Therapy and Treatment for Localized Prostate Cancer: If You Build It, They Will Come
T he number of treatment options for localized prostate cancer continues to expand, amidst growing concern regarding overdiagnosis and overtreatment of low-risk disease. [1] [2] [3] Treatment patterns, however, may be driven by availability of novel tech-nologies rather than by clinical indications. We aimed to examine regional treatment choices of men diagnosed as having localized prostate cancer living inside or outside of a defined hospital referral region containing a proton beam cyclotron in California.
Methods. We performed a retrospective cross-sectional analysis of men with prostate cancer identified through the California Cancer Registry from 2003 to 2006. Inclusion criteria were low-to intermediate-risk prostate cancer, defined by clinical stage (ՅT2c) and well-to moderately differentiated histology (Gleason score Յ7). Patients were grouped according to their hospital referral region (HRR) at time of diagnosis, as defined by the Dartmouth Atlas group (http://www.dartmouthatlas.org). 4 In brief, HRRs represent regional health care markets for tertiary medical care. Four HRRs extending into neighboring states were excluded.
Our primary predictor was a binary variable signifying whether a man was living in the HRR for San Bernardino, California (SBHRR), where the proton beam facility resides at Loma Linda University. The primary dichotomous outcome was prostate cancer treatment by proton beam therapy vs treatment by other modalities (including active surveillance). Prostate cancer treatment patterns were analyzed by HRR using logistic regression models. All candidate predictors were included in a multivariable model, including age, tumor grade, stage of cancer, race/ethnicity, year of diagnosis, and residence in the SBHRR. Statistical analyses were performed using SAS v9.2 software (SAS Institute Inc). The institutional review board at the University of California, San Francisco, approved the study.
Results. A total of 19 816 patients met inclusion criteria. Mean age and tumor stage were similar for those liv- 5% vs 1.7%; Figure) . Mean (SD) proton beam therapy rate was 2.3% (1.4%), and the range of patients treated by HRR was 0 to 142 for this period. Redding HRR showed the next highest rate of proton beam therapy; however, 184 patients were from that HRR, so this rate is based on only 13 patients receiving this treatment.
Patients living in the SBHRR were more likely to be treated with the proton beam therapy than if they lived outside of the SBHRR in univariate analysis (odds ratio [ 
Comment.
No prostate cancer treatment has been proven superior to the others. 5 There are, however, substantial differences in cost, which are becoming more important to society and are a focus of health care reform in the United States. 6, 7 While there are theoretical advantages to proton beam therapy from a radiation physics standpoint, no study yet has demonstrated its superiority to modern photon-based therapy in terms of either oncologic or quality of life outcomes. 8, 9 To our knowledge, we show for the first time that the availability of a technology, in this instance a proton beam facility, in one's HRR is associated with a higher likelihood of receiving proton beam therapy compared with those living in an HRR where this technology is not available. A single physician might explain the higher-than-expected rate of proton beam therapy in the Redding, California, HRR, since there are relatively low numbers of overall patients from this area. Interestingly, selfdescription as non-Hispanic white was also associated significantly with increased odds of receiving proton therapy-hinting at a possible racial disparity requiring further investigation.
There were several limitations: (1) Our prostate cancer risk stratification does not include prostate-specific antigen levels or Gleason scores because these are not included in the CCR. (2) Unmeasured confounding may exist, but the association of living in the SBHRR and receiving proton beam therapy is large. (3) Registry data are limited in clinical detail and may be biased through underreporting. However, there should not be systematic bias as the unreported cases are likely to have the same treatment distribution as the reported cases.
Proton beam therapy has not been shown to be superior to other treatments for prostate cancer and is substantially more expensive. 7 Caution should be taken when considering implementation of this tech-Previous Presentation: This study was presented at the American Urological Association meeting; May 15, 2011; Washington, DC.
